NewAmsterdam Pharma Co N.V. has announced a significant ownership update through its recent filing with the SEC, revealing that FMR LLC holds a 10% stake in the company. This move underscores FMR LLC's confidence in NewAmsterdam Pharma's potential for growth in the competitive pharmaceutical preparations industry.

NewAmsterdam Pharma, which trades under the ticker symbols NAMS and NAMSW on the Nasdaq, operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company has been actively engaging with investors and stakeholders, as evidenced by its recent filings, including a 10-Q and an 8-K.

According to the Schedule 13G/A filed on November 5, 2026, FMR LLC reported beneficial ownership of 11,941,763 shares of NewAmsterdam Pharma, which represents 10% of the company's common stock. The filing indicates that FMR LLC has sole voting and dispositive power over these shares. Abigail P. Johnson, a prominent figure in FMR LLC, also holds a significant interest in the company.

The filing further details that members of the Johnson family are predominant owners of Series B voting common shares of FMR LLC, which grants them considerable influence within the company. This structure may enhance FMR LLC's commitment to NewAmsterdam Pharma, potentially benefiting the pharmaceutical company's strategic direction.

FMR LLC's stake in NewAmsterdam Pharma could impact various stakeholders, including current and prospective investors, as well as competitors in the pharmaceutical sector. The increase in ownership may signal a strong belief in NewAmsterdam Pharma's future, which could lead to increased interest from other institutional investors.

As for what's next, the filing does not specify any immediate actions or upcoming events related to this ownership change. However, the market will likely keep a close watch on NewAmsterdam Pharma's performance and any further disclosures from FMR LLC or other significant shareholders.